Altimmune (ALT) Price & Analysis

Compare

3,553 Followers

ALT Stock Chart & Stats

$4.08

$0.16(2.19%)

At close: Jan 08 4:00 PM EST

$4.08

$0.16(2.19%)

Day’s Range― - ―

52-Week Range$2.90 - $7.83

Previous CloseN/A

Volume1.55M

Average Volume (3M)4.97M

Market Cap

$437.19M

Enterprise Value$142.19M

Total Cash (Recent Filing)$210.78M

Total Debt (Recent Filing)$15.90M

Price to Earnings (P/E)―

Beta1.65

Next Earnings

Mar 26, 2026

EPS Estimate

-0.24

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.21

Shares Outstanding104,342,384

10 Day Avg. Volume5,841,665

30 Day Avg. Volume4,969,376

Financial Highlights & Ratios

PEG Ratio0.28

Price to Book (P/B)4.14

Price to Sales (P/S)25596.73

P/FCF Ratio-6.41

Enterprise Value/Market Cap0.33

Enterprise Value/Revenue7.11K

Enterprise Value/Gross Profit-9.52

Enterprise Value/Ebitda-1.70

Forecast

1Y Price Target

$13.00

Price Target Upside218.63% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Efficacy48-week and earlier trial readouts showing sustained weight loss and consistent improvements in non-invasive liver measures, including MASH resolution without fibrosis worsening, support a differentiated clinical profile for pemvidutide.

Corporate PositioningStrengthened leadership, demonstrated business development momentum and an expanded financing facility provide organizational readiness and financial flexibility ahead of Phase 3 initiation.

Safety And TolerabilityHigh tolerability with lower discontinuation rates than placebo and no reported serious treatment-related adverse events could enhance patient persistence and ease enrollment in registrational studies.

Bears Say

Competitive RiskIntensifying competition and a trend toward combination approaches in MASH demand clear clinical differentiation, otherwise commercial uptake and market share could be limited.

Operational And Financial RiskClinical development setbacks, reimbursement and pricing challenges, capital market pressure or dilution, and potential trial disruptions from geopolitical or public health events could delay programs and negatively affect valuation.

Regulatory RiskFDA emphasis on biopsy-based endpoints and reluctance to fully accept non-invasive tests could require more burdensome trial designs and increase approval uncertainty.

Altimmune News

Midday Fly By: U.S. oil majors rise on Venezuela news, Versant completes spinoff

The major averages were broadly higher near noon as the markets begin their first full trading week of...

4d ago

ALT

Altimmune receives FDA breakthrough therapy designation for pemvidutide

Altimmune (ALT) announced the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation (BTD) for pemvidutide, a...

5d ago

ALT

Midday Fly By: Nike reports Q2 beat, TikTok to sell U.S. unit

The major averages were broadly higher near noon as the last full trading week of the year ends...

21d ago

Altimmune sinks 21% to $3.98 after Phase 2b MASH data

10:52 EST Altimmune (ALT) sinks 21% to $3.98 after Phase 2b MASH data Published first on TheFly –...

22d ago

ALT

Altimmune reports ‘positive’ results from IMPACT Phase 2b trial of pemvidutide

Altimmune (ALT) announced positive topline results from the IMPACT Phase 2b trial of pemvidutide, a balanced 1:1 glucagon/GLP-1...

22d ago

ALT

Altimmune put volume heavy and directionally bearish

Bearish flow noted in Altimmune (ALT) with 3,340 puts trading, or 4x expected. Most active are 12/12 weekly...

30d ago

ALT

Altimmune, Pure Storage, Globalstar, Cipher Mining, AutoZone Shake-Up

Insiders have been trading these 5 stocks: (($ALT)), (($PSTG)), (($GSAT)), (($CIFR)) and (($AZO)). Here is a breakdown of...

14d ago

ALT

AZO

Altimmune’s IMPACT NASH Trial Completion Puts Pemvidutide Back in the Spotlight

Altimmune ($ALT) announced an update on their ongoing clinical study. Altimmune’s IMPACT trial, officially titled “A Phase 2,...

14d ago

ALT

Pemvidutide’s Strong Phase 2b Data and De-Risked Phase 3 Path in MASH Support Altimmune Buy Rating and $12 Target

Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Altimmune, retaining the price target of $12.00....

22d ago

ALT

Balanced Risk-Reward for Altimmune’s Pemvidutide in a Crowded MASH Landscape Supports Hold Rating

William Blair analyst Andy Hsieh has maintained their neutral stance on ALT stock, giving a Hold rating today....

22d ago

ALT

Altimmune reports positive Phase 2b pemvidutide MASH results

Altimmune ( ($ALT) ) has issued an update. On December 19, 2025, Altimmune reported positive 48-week topline results...

22d ago

ALT

Altimmune call volume above normal and directionally bullish

Bullish option flow detected in Altimmune (ALT) with 11,726 calls trading, 1.7x expected, and implied vol increasing over...

1M ago

ALT

Altimmune Announces CEO Transition Plan

Altimmune ( ($ALT) ) has issued an update. On December 1, 2025, Altimmune announced a CEO transition plan...

1M ago

ALT

Altimmune CEO Vipin Garg to step down, Jerry Durso to succeed

Altimmune (ALT) announced a CEO succession plan under which Vipin Garg, Ph.D. will step down as the Company’s...

1M ago

ALT

ALT FAQ

What was Altimmune Inc’s price range in the past 12 months?

Altimmune Inc lowest stock price was $2.90 and its highest was $7.83 in the past 12 months.

What is Altimmune Inc’s market cap?

Altimmune Inc’s market cap is $437.19M.

When is Altimmune Inc’s upcoming earnings report date?

Altimmune Inc’s upcoming earnings report date is Mar 26, 2026 which is in 75 days.

How were Altimmune Inc’s earnings last quarter?

Altimmune Inc released its earnings results on Nov 06, 2025. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.272 by $0.062.

Is Altimmune Inc overvalued?

According to Wall Street analysts Altimmune Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Altimmune Inc pay dividends?

Altimmune Inc pays a Monthly dividend of $873 which represents an annual dividend yield of N/A. See more information on Altimmune Inc dividends here

What is Altimmune Inc’s EPS estimate?

Altimmune Inc’s EPS estimate is -0.24.

How many shares outstanding does Altimmune Inc have?

Altimmune Inc has 104,342,384 shares outstanding.

What happened to Altimmune Inc’s price movement after its last earnings report?

Altimmune Inc reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.272. Following the earnings report the stock price went up 5.067%.

Which hedge fund is a major shareholder of Altimmune Inc?

Currently, no hedge funds are holding shares in ALT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Altimmune Stock Smart Score

Neutral

Fundamentals

Return on Equity

-52.61%

Trailing 12-Months

Asset Growth

47.73%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Altimmune Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Altimmune (ALT) Earnings & Revenues

Historic Earnings Reports

ALT Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflected a positive outlook with significant financial growth, clinical progress in key trials, and strategic leadership enhancements. However, there are challenges related to the timing of clinical operations and dependency on regulatory changes, which could impact future trial designs and approvals.View all ALT earnings summaries

ALT Stock 12 Month Forecast

Average Price Target

$13.00

▲(218.63% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","15":"$15","5.25":"$5.25","8.5":"$8.5","11.75":"$11.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$13.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,5.25,8.5,11.75,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.61,4.409230769230769,5.208461538461538,6.007692307692308,6.806923076923077,7.6061538461538465,8.405384615384616,9.204615384615385,10.003846153846155,10.803076923076924,11.602307692307694,12.401538461538461,13.20076923076923,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.61,4.332307692307692,5.054615384615385,5.776923076923077,6.499230769230769,7.2215384615384615,7.943846153846154,8.666153846153845,9.388461538461538,10.11076923076923,10.833076923076923,11.555384615384614,12.277692307692307,{"y":13,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.61,4.2553846153846155,4.900769230769231,5.546153846153846,6.191538461538462,6.836923076923076,7.4823076923076925,8.127692307692309,8.773076923076923,9.418461538461539,10.063846153846153,10.70923076923077,11.354615384615386,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.21,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.64,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.65,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.74,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.17,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.3,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.23,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.61,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.75,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.87,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.05,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.93,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.61,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >